↓ Skip to main content

Recent progress and considerations for AAV gene therapies targeting the central nervous system

Overview of attention for article published in Journal of Neurodevelopmental Disorders, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

blogs
1 blog
twitter
6 X users
patent
10 patents

Citations

dimensions_citation
112 Dimensions

Readers on

mendeley
280 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Published in
Journal of Neurodevelopmental Disorders, May 2018
DOI 10.1186/s11689-018-9234-0
Pubmed ID
Authors

Erik Allen Lykken, Charles Shyng, Reginald James Edwards, Alejandra Rozenberg, Steven James Gray

Abstract

Neurodevelopmental disorders, as a class of diseases, have been particularly difficult to treat even when the underlying cause(s), such as genetic alterations, are understood. What treatments do exist are generally not curative and instead seek to improve quality of life for affected individuals. The advent of gene therapy via gene replacement offers the potential for transformative therapies to slow or even stop disease progression for current patients and perhaps minimize or prevent the appearance of symptoms in future patients. This review focuses on adeno-associated virus (AAV) gene therapies for diseases of the central nervous system. An overview of advances in AAV vector design for therapy is provided, along with a description of current strategies to develop AAV vectors with tailored tropism. Next, progress towards treatment of neurodegenerative diseases is presented at both the pre-clinical and clinical stages, focusing on a few select diseases to highlight broad categories of therapeutic parameters. Special considerations for more challenging cases are then discussed in addition to the immunological aspects of gene therapy. With the promising clinical trial results that have been observed for the latest AAV gene therapies and continued pre-clinical successes, the question is no longer whether a therapy can be developed for certain neurodevelopmental disorders, but rather, how quickly.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 280 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 280 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 54 19%
Student > Ph. D. Student 53 19%
Student > Bachelor 27 10%
Other 22 8%
Student > Master 22 8%
Other 30 11%
Unknown 72 26%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 71 25%
Neuroscience 44 16%
Agricultural and Biological Sciences 26 9%
Medicine and Dentistry 19 7%
Pharmacology, Toxicology and Pharmaceutical Science 14 5%
Other 24 9%
Unknown 82 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2024.
All research outputs
#1,606,464
of 23,505,669 outputs
Outputs from Journal of Neurodevelopmental Disorders
#54
of 486 outputs
Outputs of similar age
#36,293
of 330,214 outputs
Outputs of similar age from Journal of Neurodevelopmental Disorders
#1
of 8 outputs
Altmetric has tracked 23,505,669 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 486 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,214 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them